• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Latest Research Insights on Acetamidine-d3 Hydrochloride (CAS: 74929-88-7) in Chemical Biology and Pharmaceutical Applications

Acetamidine-d3 Hydrochloride (CAS: 74929-88-7), a deuterated analog of acetamidine, has garnered significant attention in recent chemical biology and pharmaceutical research due to its utility as a stable isotope-labeled reagent. This compound is particularly valued for its role in mass spectrometry-based proteomics, metabolic studies, and drug metabolism research, where deuterium labeling enhances analytical precision. Recent studies highlight its application in tracing biochemical pathways and improving the detection sensitivity of small molecules in complex biological matrices.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of Acetamidine-d3 Hydrochloride as a key intermediate in the synthesis of deuterated pharmaceuticals, emphasizing its ability to improve pharmacokinetic profiles by reducing metabolic degradation. The deuterium kinetic isotope effect (DKIE) conferred by the compound was shown to prolong the half-life of experimental drugs targeting enzyme inhibition, such as serine proteases. Researchers utilized nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS) to validate the structural integrity and isotopic purity of synthesized derivatives.

Further advancements were reported in a 2024 ACS Chemical Biology paper, where Acetamidine-d3 Hydrochloride was employed to investigate arginine methylation dynamics in epigenetics. The study leveraged the compound’s isotopic signature to quantify methyltransferase activity, revealing novel regulatory mechanisms in cancer cell lines. This approach provided a template for developing targeted epigenetic therapies with reduced off-target effects.

In the pharmaceutical industry, Acetamidine-d3 Hydrochloride has been instrumental in optimizing drug formulations. A collaborative project between academic and industrial researchers (detailed in European Journal of Pharmaceutical Sciences, 2023) utilized the compound to trace excipient interactions in solid dispersions, enhancing bioavailability predictions for poorly soluble drugs. The study underscored the reagent’s versatility in both early-stage discovery and formulation science.

Despite its advantages, challenges remain in large-scale synthesis and cost-effectiveness. Current research (e.g., Organic Process Research & Development, 2024) focuses on catalytic deuteration methods to streamline production. These efforts aim to expand access to high-purity Acetamidine-d3 Hydrochloride for global research communities while maintaining compliance with green chemistry principles.

In conclusion, Acetamidine-d3 Hydrochloride (74929-88-7) continues to be a pivotal tool in advancing precision medicine and mechanistic studies. Its dual role as a metabolic tracer and synthetic building block positions it at the forefront of innovations in drug development and biochemical research. Future directions may explore its applications in CRISPR-based gene editing and targeted protein degradation therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)